Projections of HCV-related disease outcomes for Scenario 1-B, over the period 1960–2039.

Model predictions assuming 60% chronic HCV prevalence and 30% or 50% of the people who inject drugs sharing injection equipment.

Ilias Gountas (5638439)
Vana Sypsa (146060)
Sarah Blach (760026)
Homie Razavi (760027)
Angelos Hatzakis (146074)

August 2018

We assumed that no treatment is provided after 2030.Mean time of HCV acquisition greater than 25 yea...

Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection

Seyed Hamid Moosavy
Parivash Davoodian
Mirza Ali Nazarnezhad
Abdolazim Nejatizaheh
Ebrahim Eftekhar
Hamidreza Mahboobi

October 2017

Hepatitis C infection is one of the main causes of chronic liver disorders worldwide. Nearly three p...

Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by year of study enrollment in: A) the overall population; B) those with person-years of injecting during follow-up; and calendar year of observation in: C) the overall population; and D) those with person-years of injecting during follow-up.

Jason Grebely (124046)
Viviane Dias Lima (37207)
Brandon D. L. Marshall (307824)
M-J Milloy (572735)
Kora DeBeck (572736)
Julio Montaner (170627)
Annick Simo (572737)
Mel Krajden (480863)
Gregory J. Dore (205555)
Thomas Kerr (297068)
Evan Wood (297066)

June 2014

The circles indicate the HCV incidence density (per 100 person years) and the lines indicate the ...

Projected HCV-related disease burden in DALYs/year, over the period 1960–2039.

Scott A. McDonald (749521)
Maznah Dahlui (625566)
Rosmawati Mohamed (132206)
Herlianna Naning (749522)
Fatiha Hana Shabaruddin (749523)
Adeeba Kamarulzaman (307011)

June 2015

Three historical incidence scenarios are compared (1-B, 2-B, and 3-B), with current treatment upt...

Patterns of acute incidence underlying Scenarios 1 to 3.

Scott A. McDonald (749521)
Maznah Dahlui (625566)
Rosmawati Mohamed (132206)
Herlianna Naning (749522)
Fatiha Hana Shabaruddin (749523)
Adeeba Kamarulzaman (307011)

June 2015

The assumed historical HCV incidence time series for Scenarios 1 to 3 are shown separately for PW...

Forecast of HCV antibody prevalence in Chicago over a 10-year span, 2010–2020.

Alexander Gutfraind (237693)
Basmattee Boodram (785945)
Nikhil Prachand (801682)
Atesmachew Hailegiorgis (801683)
Harel Dahari (390003)
Marian E. Major (801684)

September 2015

(A) HCV antibody prevalence based on location, Suburban and City, and age, persons over and under...

Projected preventive effect of treating earlier into infection (Scenario B).

Nicolas Durier (326615)
Chi Nguyen (326616)
Lisa J. White (101780)

February 2013

Panel A): Reduction of anti-HCV antibody prevalence following treatment of 50% of chronically inf...

Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway

Kileng, H.
Bernfort, Lars
Gutteberg, T.
Moen, O. S.
Kristiansen, M. G.
Paulssen, E. J.
Berg, L. K.
Florholmen, J.
Goll, R.

January 2017

Background: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected in...

Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by calendar year of enrolment and calendar year of observation.

Jason Grebely (124046)
Viviane Dias Lima (37207)
Brandon D. L. Marshall (307824)
M-J Milloy (572735)
Kora DeBeck (572736)
Julio Montaner (170627)
Annick Simo (572737)
Mel Krajden (480863)
Gregory J. Dore (205555)
Thomas Kerr (297068)
Evan Wood (297066)

June 2014

Each shaded area is a proportion relative to the largest incidence rate with 25.0 being 1 (full s...

Projected preventive effect of increasing hepatitis C treatment coverage (Scenario A).

Nicolas Durier (326615)
Chi Nguyen (326616)
Lisa J. White (101780)

February 2013

Panel A): Reduction of anti-HCV antibody prevalence following treatment introduction and scale up...

Final model showing association of factors with HCV sero-prevalence among IDUs.

Lei Li (29537)
Sawitri Assanangkornchai (627530)
Lin Duo (357167)
Edward McNeil (627531)
Jianhua Li (36075)

September 2014

aAOR = Adjusted odds ratio.b95% CI = 95% confidence interval.Final model showing as...

Estimated prevalence of CHC patients.

Kittiyod Poovorawan (732725)
Wirichada Pan-ngum (101734)
Lisa J. White (101780)
Ngamphol Soonthornworasiri (3121773)
Polrat Wilairatana (50854)
Rujipat Wasitthankasem (732723)
Pisit Tangkijvanich (513614)
Yong Poovorawan (39511)

September 2016

Estimated prevalence of patients with CHC based on previous data and transmission and progression...

Short term epidemiological hepatitis c virus impact among HIV positive men who have sex with men.

Stephanie Popping (6195134)
Sebastiaan J. Hullegie (3152973)
Anne Boerekamps (6195137)
Bart J. A. Rijnders (248260)
Robert J. de Knegt (121494)
Jürgen K. Rockstroh (355014)
Annelies Verbon (175842)
Charles A. B. Boucher (306753)
Brooke E. Nichols (390862)
David A. M. C. van de Vijver (363430)

January 2019

In the upper figure, the hepatitis C virus incidence is projected and in the lower figure the hepati...

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data

Kershenobich, David
Razavi, Homie A
Cooper, Curtis L
Alberti, Alfredo
Dusheiko, Geoffrey M
Pol, Stanislas
Zuckerman, Eli
Koike, Kazuhiko
Han, Kwang-Hyub
Wallace, Carolyn M
Zeuzem, Stefan
Negro, Francesco

January 2011

Hepatitis C virus (HCV) infection is associated with chronic progressive liver disease. Its global e...

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

Gane, E
Kershenobich, D
Seguin-Devaux, C
Kristian, P
Aho, I
Dalgard, O
Shestakova, I
Nymadawa, P
Blach, S
Acharya, S
Anand, AC
Andersson, MI
Arendt, V
Arkkila, P
Baatarkhuu, O
Barclay, K
Ben-Ari, Z
Bergin, C
Bessone, F
Blokhina, N
Brunton, CR
Choudhuri, G
Chulanov, V
Cisneros, L
Croes, EA
Dahgwahdorj, YA
Daruich, JR
Dashdorj, NR
Davaadorj, D
de Knegt, Rob
de Vree, M
Gadano, AC
Gower, E
Halota, W
Hatzakis, A
Henderson, C
Hoffmann, P
Hornell, J
Houlihan, D
Hrusovsky, S
Jarcuska, P
Kostrzewska, K
Leshno, M
Lurie, Y
Mahomed, A
Mamonova, N
Mendez-Sanchez, N
Mossong, J
Norris, S
Nurmukhametova, E
Oltman, M
Oyunbileg, J
Oyunsuren, T
Papatheodoridis, G
Pimenov, N
Prins, M
Puri, P
Radke, S
Rakhmanova, A
Razavi, H
Razavi-Shearer, K
Reesink, HW
Ridruejo, E
Safadi, R
Sagalova, O
Sanchez Avila, JF
Sanduijav, R
Saraswat, V
Schreter, I
Shah, SR
Shevaldin, A
Shibolet, O
Silva, MO
Sokolov, S
Sonderup, M
Souliotis, K
Spearman, CW
Staub, T
Stedman, C
Strebkova, EA
Struck, D
Sypsa, V
Tomasiewicz, K
Undram, L
van der Meer, Adriaan
van Santen, D
Veldhuijzen, I
Villamil, FG
Willemse, S
Zuckerman, E
Zuure, FR
Prabdial-Sing, N
Flisiak, R
Estes, C

January 2015

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative ...

Model predictions assuming 60% chronic HCV prevalence and 30% or 50% of the people who inject drugs sharing injection equipment.

Ilias Gountas (5638439)
Vana Sypsa (146060)
Sarah Blach (760026)
Homie Razavi (760027)
Angelos Hatzakis (146074)

August 2018

We assumed that no treatment is provided after 2030.Mean time of HCV acquisition greater than 25 yea...

Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection

Seyed Hamid Moosavy
Parivash Davoodian
Mirza Ali Nazarnezhad
Abdolazim Nejatizaheh
Ebrahim Eftekhar
Hamidreza Mahboobi

October 2017

Hepatitis C infection is one of the main causes of chronic liver disorders worldwide. Nearly three p...

Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by year of study enrollment in: A) the overall population; B) those with person-years of injecting during follow-up; and calendar year of observation in: C) the overall population; and D) those with person-years of injecting during follow-up.

Jason Grebely (124046)
Viviane Dias Lima (37207)
Brandon D. L. Marshall (307824)
M-J Milloy (572735)
Kora DeBeck (572736)
Julio Montaner (170627)
Annick Simo (572737)
Mel Krajden (480863)
Gregory J. Dore (205555)
Thomas Kerr (297068)
Evan Wood (297066)

June 2014

The circles indicate the HCV incidence density (per 100 person years) and the lines indicate the ...

Projected HCV-related disease burden in DALYs/year, over the period 1960–2039.

Scott A. McDonald (749521)
Maznah Dahlui (625566)
Rosmawati Mohamed (132206)
Herlianna Naning (749522)
Fatiha Hana Shabaruddin (749523)
Adeeba Kamarulzaman (307011)

June 2015

Three historical incidence scenarios are compared (1-B, 2-B, and 3-B), with current treatment upt...

Patterns of acute incidence underlying Scenarios 1 to 3.

Scott A. McDonald (749521)
Maznah Dahlui (625566)
Rosmawati Mohamed (132206)
Herlianna Naning (749522)
Fatiha Hana Shabaruddin (749523)
Adeeba Kamarulzaman (307011)

June 2015

The assumed historical HCV incidence time series for Scenarios 1 to 3 are shown separately for PW...

Forecast of HCV antibody prevalence in Chicago over a 10-year span, 2010–2020.

Alexander Gutfraind (237693)
Basmattee Boodram (785945)
Nikhil Prachand (801682)
Atesmachew Hailegiorgis (801683)
Harel Dahari (390003)
Marian E. Major (801684)

September 2015

(A) HCV antibody prevalence based on location, Suburban and City, and age, persons over and under...

Projected preventive effect of treating earlier into infection (Scenario B).

Nicolas Durier (326615)
Chi Nguyen (326616)
Lisa J. White (101780)

February 2013

Panel A): Reduction of anti-HCV antibody prevalence following treatment of 50% of chronically inf...

Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway

Kileng, H.
Bernfort, Lars
Gutteberg, T.
Moen, O. S.
Kristiansen, M. G.
Paulssen, E. J.
Berg, L. K.
Florholmen, J.
Goll, R.

January 2017

Background: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected in...

Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by calendar year of enrolment and calendar year of observation.

Jason Grebely (124046)
Viviane Dias Lima (37207)
Brandon D. L. Marshall (307824)
M-J Milloy (572735)
Kora DeBeck (572736)
Julio Montaner (170627)
Annick Simo (572737)
Mel Krajden (480863)
Gregory J. Dore (205555)
Thomas Kerr (297068)
Evan Wood (297066)

June 2014

Each shaded area is a proportion relative to the largest incidence rate with 25.0 being 1 (full s...

Projected preventive effect of increasing hepatitis C treatment coverage (Scenario A).

Nicolas Durier (326615)
Chi Nguyen (326616)
Lisa J. White (101780)

February 2013

Panel A): Reduction of anti-HCV antibody prevalence following treatment introduction and scale up...

Final model showing association of factors with HCV sero-prevalence among IDUs.

Lei Li (29537)
Sawitri Assanangkornchai (627530)
Lin Duo (357167)
Edward McNeil (627531)
Jianhua Li (36075)

September 2014

aAOR = Adjusted odds ratio.b95% CI = 95% confidence interval.Final model showing as...

Estimated prevalence of CHC patients.

Kittiyod Poovorawan (732725)
Wirichada Pan-ngum (101734)
Lisa J. White (101780)
Ngamphol Soonthornworasiri (3121773)
Polrat Wilairatana (50854)
Rujipat Wasitthankasem (732723)
Pisit Tangkijvanich (513614)
Yong Poovorawan (39511)

September 2016

Estimated prevalence of patients with CHC based on previous data and transmission and progression...

Short term epidemiological hepatitis c virus impact among HIV positive men who have sex with men.

Stephanie Popping (6195134)
Sebastiaan J. Hullegie (3152973)
Anne Boerekamps (6195137)
Bart J. A. Rijnders (248260)
Robert J. de Knegt (121494)
Jürgen K. Rockstroh (355014)
Annelies Verbon (175842)
Charles A. B. Boucher (306753)
Brooke E. Nichols (390862)
David A. M. C. van de Vijver (363430)

January 2019

In the upper figure, the hepatitis C virus incidence is projected and in the lower figure the hepati...

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data

Kershenobich, David
Razavi, Homie A
Cooper, Curtis L
Alberti, Alfredo
Dusheiko, Geoffrey M
Pol, Stanislas
Zuckerman, Eli
Koike, Kazuhiko
Han, Kwang-Hyub
Wallace, Carolyn M
Zeuzem, Stefan
Negro, Francesco

January 2011

Hepatitis C virus (HCV) infection is associated with chronic progressive liver disease. Its global e...

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

Gane, E
Kershenobich, D
Seguin-Devaux, C
Kristian, P
Aho, I
Dalgard, O
Shestakova, I
Nymadawa, P
Blach, S
Acharya, S
Anand, AC
Andersson, MI
Arendt, V
Arkkila, P
Baatarkhuu, O
Barclay, K
Ben-Ari, Z
Bergin, C
Bessone, F
Blokhina, N
Brunton, CR
Choudhuri, G
Chulanov, V
Cisneros, L
Croes, EA
Dahgwahdorj, YA
Daruich, JR
Dashdorj, NR
Davaadorj, D
de Knegt, Rob
de Vree, M
Gadano, AC
Gower, E
Halota, W
Hatzakis, A
Henderson, C
Hoffmann, P
Hornell, J
Houlihan, D
Hrusovsky, S
Jarcuska, P
Kostrzewska, K
Leshno, M
Lurie, Y
Mahomed, A
Mamonova, N
Mendez-Sanchez, N
Mossong, J
Norris, S
Nurmukhametova, E
Oltman, M
Oyunbileg, J
Oyunsuren, T
Papatheodoridis, G
Pimenov, N
Prins, M
Puri, P
Radke, S
Rakhmanova, A
Razavi, H
Razavi-Shearer, K
Reesink, HW
Ridruejo, E
Safadi, R
Sagalova, O
Sanchez Avila, JF
Sanduijav, R
Saraswat, V
Schreter, I
Shah, SR
Shevaldin, A
Shibolet, O
Silva, MO
Sokolov, S
Sonderup, M
Souliotis, K
Spearman, CW
Staub, T
Stedman, C
Strebkova, EA
Struck, D
Sypsa, V
Tomasiewicz, K
Undram, L
van der Meer, Adriaan
van Santen, D
Veldhuijzen, I
Villamil, FG
Willemse, S
Zuckerman, E
Zuure, FR
Prabdial-Sing, N
Flisiak, R
Estes, C

January 2015

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative ...

Model predictions assuming 60% chronic HCV prevalence and 30% or 50% of the people who inject drugs sharing injection equipment.

Ilias Gountas (5638439)
Vana Sypsa (146060)
Sarah Blach (760026)
Homie Razavi (760027)
Angelos Hatzakis (146074)

August 2018

We assumed that no treatment is provided after 2030.Mean time of HCV acquisition greater than 25 yea...

Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection

Seyed Hamid Moosavy
Parivash Davoodian
Mirza Ali Nazarnezhad
Abdolazim Nejatizaheh
Ebrahim Eftekhar
Hamidreza Mahboobi

October 2017

Hepatitis C infection is one of the main causes of chronic liver disorders worldwide. Nearly three p...

Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by year of study enrollment in: A) the overall population; B) those with person-years of injecting during follow-up; and calendar year of observation in: C) the overall population; and D) those with person-years of injecting during follow-up.

Jason Grebely (124046)
Viviane Dias Lima (37207)
Brandon D. L. Marshall (307824)
M-J Milloy (572735)
Kora DeBeck (572736)
Julio Montaner (170627)
Annick Simo (572737)
Mel Krajden (480863)
Gregory J. Dore (205555)
Thomas Kerr (297068)
Evan Wood (297066)

June 2014

The circles indicate the HCV incidence density (per 100 person years) and the lines indicate the ...

Projections of HCV-related disease outcomes for Scenario 1-B, over the period 1960–2039.

Abstract

Extracted data

Projections of HCV-related disease outcomes for Scenario 1-B, over the period 1960–2039.

Abstract

Extracted data

Related items

Related items